Medtronic has received CE Mark for the Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. The Aurora EV-ICD system provides the life-saving benefits of traditional ICDs while avoiding certain risks because its lead is placed outside the heart and veins. The Aurora EV-ICD system is investigational in the United States. Patients implanted with the Aurora EV-ICD system have defibrillation, anti-tachycardia pacing, and back-up pacing therapies available to them via a single implanted device that is similar in size, shape, and longevity to traditional ICDs. The system approval also includes proprietary procedure implant tools. The Aurora EV-ICD system is expected to be commercially available in autumn 2023 in select countries in Europe.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MDT:
- Medtronic put volume heavy and directionally bearish
- Apple names Medtronic’s Surface as Chief People Officer, Bloomberg says
- Medtronic announces late-breaking clinical data from STROKE AF trial
- Bernstein medical tech/devices analysts hold analyst/industry conference call
- Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
